Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials
The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Aim This article provides the first comprehensive meta-analysis of randomized clinical trials of medications for obesity.Method Based on stringent inclusionary criteria, a total of 108 studies were included in the final database. Outcomes are presented for comparisons of single and combination drugs to placebo and for comparisons of medications to one another.Result Overall, the medications studied produced medium effect sizes. Four drugs produced large effect sizes (ie d>0.80; amphetamine, benzphetamine, fenfluramine and sibutramine). The placebo-subtracted weight losses for single drugs vs placebo included in the meta-analysis never exceeded 4.0 kg. No drug, or class of drugs, demonstrated clear superiority as an obesity medication. Effects of methodological factors are also presented along with suggestions for future research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a meta-analysis of phentermine monotherapy clinical trials, the placebo-corrected reduction in body weight with phentermine was less than 4 kg”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [49]
In the citing paper
“The pooled analysis showed that those treated with phentermine along with diet and lifestyle lost 3.6 kg more than patients treated with diet and lifestyle alone.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [196]
Citations
Cites
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
Lipsey, M. W., & Wilson, D. B. (1993) · American Psychologist · doi:10.1037/0003-066x.48.12.1181 · Cited by 2,033
Estimation of effect size from a series of independent experiments.
Hedges, L. V. (1982) · Psychological Bulletin · doi:10.1037//0033-2909.92.2.490 · Cited by 1,062
The Handbook of Research Synthesis
Hanka, R. (1994) · BMJ · doi:10.1136/bmj.309.6952.488a · Cited by 1,052
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Phenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T., Feldmann, E., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432501 · Cited by 611
Research works printed but not linked: 3
- Scoville BA . Review of amphetamine like drugs by the Federal Drug Administration: clinical data and value judgments. In: G Bray (ed). Obesity in perspective, DHEW publication no. (NIH) 75–708. US Government Printing Office: Washington, DC 1973.
- Shadish, WR, Haddock, CK . Combining estimates of effect size. In: H Cooper, LV Hedges (eds). The handbook of research synthesis Russell Sage: New York 1994 261–281.
- National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity: the evidence report US Government Press: Washington DC 1998.
Cited by
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
“A recently published meta-analysis concerning the efficacy of pharmacological agents for obesity reported that an average weight loss was approximately four kilograms more than for placebo users and that no drug or class of drugs was clearly superior [172].”
BackgroundRetractedFranz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
“Our literature search identified a recent meta-analysis (74) that assessed RCTs of the use of phentermine for weight loss in obese individuals.”
MethodDrug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 593
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study
Gray, R. H., Li, X., Kigozi, G., Serwadda, D., Brahmbhatt, H., Wabwire-Mangen, F., Nalugoda, F., Kiddugavu, M., Sewankambo, N., Quinn, T. C., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67481-8 · Cited by 358
Padwal, R., Li, S. K., & Lau, D. C. W. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802475 · Cited by 348
Snow, V., Barry, P., Fitterman, N., Qaseem, A., Weiss, K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00011 · Cited by 329
Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment??of Obesity
Halford, J. C. G., Harrold, J. A., Boyland, E. J., Lawton, C. L., & Blundell, J. E. (2007) · Drugs · doi:10.2165/00003495-200767010-00004 · Cited by 307
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · Obesity · doi:10.1002/oby.20181 · Cited by 284
Nutrition and reproduction in women
The ESHRE Capri Workshop Group (2006) · Human Reproduction Update · doi:10.1093/humupd/dmk003 · Cited by 255
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Ioannides-Demos, L. L., Piccenna, L., & McNeil, J. J. (2011) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 243
Obesity after spinal cord injury
Gater, D. R. (2007) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2007.03.004 · Cited by 228
Interventions to reduce weight gain in schizophrenia
Faulkner, G., Cohn, T., & Remington, G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005148.pub2 · Cited by 222
Weight Loss Strategies for Treatment of Obesity
Kushner, R. F. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.09.005 · Cited by 219
The Metabolic Syndrome: Practical Guide to Origins and Treatment: Part I
Wilson, P. W. F., & Grundy, S. M. (2003) · Circulation · doi:10.1161/01.cir.0000089505.34741.e5 · Cited by 212
Heal, D. J., Smith, S. L., Fisas, A., Codony, X., & Buschmann, H. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.006 · Cited by 184
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176
Diets and drugs for weight loss and health in obesity – An update
Aaseth, J., Ellefsen, S., Alehagen, U., Sundfør, T. M., & Alexander, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111789 · Cited by 174
Metabolic Syndrome: From Global Epidemiology to Individualized Medicine
Batsis, J. A., Nieto-Martinez, R. E., & Lopez-Jimenez, F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100355 · Cited by 170
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 165
Ghrelin regulation of glucose metabolism
Poher, A.-L., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.015 · Cited by 186
Ioannides-Demos, L. L., Proietto, J., & McNeil, J. J. (2005) · Drugs · doi:10.2165/00003495-200565100-00006 · Cited by 165
Schizophrenia and weight management: a systematic review of interventions to control weight
Faulkner, G., Soundy, A. A., & Lloyd, K. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00218.x · Cited by 166
Ionut, V., Burch, M., Youdim, A., & Bergman, R. N. (2013) · Obesity · doi:10.1002/oby.20364 · Cited by 161
Overviews of Pathogen Emergence: Which Pathogens Emerge, When and Why?
Cleaveland, S., Haydon, D. T., & Taylor, L. H. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70962-6_5 · Cited by 200
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
Ioannides‐Demos, L. L., Proietto, J., Tonkin, A. M., & McNeil, J. J. (2006) · Drug Safety · doi:10.2165/00002018-200629040-00001 · Cited by 169
Pharmacological Therapies for Obesity
Kaplan, L. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.002 · Cited by 149
Thompson, W. G., Cook, D. A., Clark, M. M., Bardia, A., & Levine, J. A. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60971-3 · Cited by 172
Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes
Lam, D. D., & Heisler, L. K. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000245 · Cited by 142
Risks and benefits of bariatric surgery: current evidence.
Brethauer, S. A., Chand, B., & Schauer, P. R. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.11.993 · Cited by 163
Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy
Kushner, R. F. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.06.001 · Cited by 135
Behavioral and pharmacologic therapies for obesity
Vetter, M. L., Faulconbridge, L. F., Webb, V. L., & Wadden, T. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.121 · Cited by 123
Kang, J. G., Park, C. ‐., Kang, J. H., Park, Y. ‐., & Park, S. W. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01242.x · Cited by 120
Central control of thermogenesis
Clapham, J. C. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.014 · Cited by 141
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Updates on obesity pharmacotherapy
Velazquez, A., & Apovian, C. M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13542 · Cited by 115
Treating obesity in individuals and populations
Jain, A. (2005) · BMJ · doi:10.1136/bmj.331.7529.1387 · Cited by 108
Effect of Sibutramine on Weight Loss and Blood Pressure: A Meta‐analysis of Controlled Trials
Kim, S. H., Lee, Y. M., Jee, S. H., & Nam, C. M. (2003) · Obesity Research · doi:10.1038/oby.2003.152 · Cited by 106
Li, M., & Cheung, B. M. Y. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03453.x · Cited by 100
Cercato, C., Roizenblatt, V. A., Leança, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., & Halpern, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.124 · Cited by 100
Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., & Shen, L. Z. (2010) · Obesity · doi:10.1038/oby.2009.478 · Cited by 100
Weight management in obesity – past and present
Haslam, D. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12771 · Cited by 97
Childhood Overweight: An Expanding Problem
Kaur, H., Hyder, M. L., & Poston, W. S. C. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302060-00002 · Cited by 137
Self-citationBehavioral Interventions for Obesity
Berkel, L. A., Poston, W. S. C., Reeves, R. S., & Foreyt, J. P. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2005.02.031 · Cited by 109
Self-citationCurrent Management Strategies for Coexisting Diabetes Mellitus and Obesity
Scheen, A. J. (2003) · Drugs · doi:10.2165/00003495-200363120-00001 · Cited by 110
Obesity and reproduction: an educational bulletin
(2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.08.005 · Cited by 102
Cardiovascular Risk-Benefit Profile of Sibutramine
Scheen, A. J. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11584800-000000000-00000 · Cited by 96
Kim, K. K., Cho, H.-J., Kang, H.-C., Youn, B.-B., & Lee, K.-R. (2006) · Yonsei Medical Journal · doi:10.3349/ymj.2006.47.5.614 · Cited by 88
“The reports of the randomized controlled studies of phentermine had been published from 1975 to 1999, and there have been no further clinical trials on the phentermine usage since 1999.(9) Moreover, there are few reports about the effect and safety profile of phentermine in Korean.”
BackgroundRegulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
A Comprehensive Review of Metabolic Syndrome Affecting Erectile Dysfunction
Kaya‐Sezginer, E., Sikka, S. C., & Gür, S. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12828 · Cited by 88
Therapeutic Potential of 5-HT2CReceptor Agonists for Addictive Disorders
Higgins, G. A., & Fletcher, P. J. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00025 · Cited by 83
Pharmacological and surgical treatment of obesity.
Shekelle, P., Morton, S. C., Maglione, M., Suttorp, M. J., Tu, W., Li, Z., Maggard, M. A., Mojica, W., Shugarman, L. R., & Solomon, V. (2004) · PubMed Central · Cited by 83
Obesity management: what brings success?
Lagerros, Y. T., & Rössner, S. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12459413 · Cited by 82
Boswell, R. G., Potenza, M. N., & Grilo, C. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.10.014 · Cited by 96
Pharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 94
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 83
Castells, X., Casas, M., Vidal, X., Bosch, R., Roncero, C., Ramos‐Quiroga, J. A., & Capellà, D. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01943.x · Cited by 74
The role of seaweed bioactives in the control of digestion: implications for obesity treatments
Chater, P. I., Wilcox, M. D., Houghton, D., & Pearson, J. P. (2015) · Food & Function · doi:10.1039/c5fo00293a · Cited by 80
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Coffey, C. S., Steiner, D., Baker, B. A., & Allison, D. B. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802784 · Cited by 68
5-HT2C Receptor Agonists and the Control of Appetite
Halford, J. C. G., & Harrold, J. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_16 · Cited by 69
Anderson, J. W., Luan, J. J., & Høie, L. H. (2004) · Advances in Therapy · doi:10.1007/bf02850334 · Cited by 75
Halford, J. C. G. (2005) · Appetite · doi:10.1016/j.appet.2005.07.010 · Cited by 74
Serotonergic Anti-Obesity Agents: Past Experience and Future Prospects
Halford, J. C. G., Boyland, E. J., Lawton, C. L., Blundell, J. E., & Harrold, J. A. (2011) · Drugs · doi:10.2165/11596680-000000000-00000 · Cited by 64
Anderson, J. W., & Høie, L. H. (2005) · Journal of the American College of Nutrition · doi:10.1080/07315724.2005.10719467 · Cited by 71
Kumar, V., Singh, D. D., Lakhawat, S. S., Yasmeen, N., Pandey, A., & Singla, R. K. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6852276 · Cited by 71
New pharmacological approaches for obesity management
Rueda‐Clausen, C. F., Padwal, R. S., & Sharma, A. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.113 · Cited by 61
The potential use of selective 5-HT2Cagonists in treating obesity
Smith, B. M., Thomsen, W. J., & Grottick, A. J. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.257 · Cited by 62
Pharmacotherapy for Patients with Obesity
Gadde, K. M., Apolzan, J. W., & Berthoud, H.-R. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 57
Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis
Cerreto, M., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2021) · Nutrients · doi:10.3390/nu13082649 · Cited by 61
Moldovan, C. P., Weldon, A. J., Daher, N. S., Schneider, L. E., Bellinger, D. L., Berk, L. S., Hermé, A. C., Aréchiga, A. L., Davis, W. L., & Peters, W. R. (2016) · Obesity · doi:10.1002/oby.21649 · Cited by 55
Serotonin, a possible intermediate between disturbed circadian rhythms and metabolic disease
Versteeg, R. I., Serlie, M. J. M., Kalsbeek, A., & la Fleur, S. E. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.067 · Cited by 62
Pediatric Obesity: Complications and Current Day Management
Vajravelu, M. E., Tas, E., & Arslanian, S. A. (2023) · Life · doi:10.3390/life13071591 · Cited by 75
Influenza Viruses in Animal Wildlife Populations
Webby, R. J., Webster, R. G., & Richt, J. A. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70962-6_4 · Cited by 82
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity
Suplicy, H. L., Boguszewski, C. L., dos Santos, C. M. C., de Figueiredo, M. D. D., da Cunha, D. R., & Radominski, R. B. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.225 · Cited by 59
Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification
Poston, W. S. C., Reeves, R. S., Haddock, C. K., Stormer, S., Balasubramanyam, A., Satterwhite, O., Taylor, J. E., & Foreyt, J. P. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802439 · Cited by 54
Self-citationBarriers to Counseling Patients with Obesity: A Study of Texas Community Pharmacists
O'Donnell, D. C., Brown, C. M., & Dastani, H. B. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506778073565 · Cited by 56
Scheen, A. J., & Ernest, P. (2002) · PubMed · Cited by 58
Measurement of outcomes, mediators, and moderators in behavioral obesity prevention research
Baranowski, T., Klesges, L. M., Cullen, K. W., & Himes, J. H. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2003.12.029 · Cited by 59
Medications as Adjunct Therapy for Weight Loss: Approved and Off-Label Agents in Use
Moyers, S. B. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2005.03.010 · Cited by 56
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 51
POSTON, W. S. C., HADDOCK, C. K., PINKSTON, M. M., PACE, P., REEVES, R. S., KARAKOC, N., JONES, P., & FOREYT, J. P. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01702.x · Cited by 46
Self-citationMedical management of obesity associated with mental disorders.
Malhotra, S., & McElroy, S. L. (2002) · PubMed · Cited by 50
Obesity and pharmacologic therapy
Thearle, M. S., & Aronne, L. J. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00066-5 · Cited by 52
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 51
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 55
Pharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 41
Sibutramine and the management of obesity
Poston, W. S. C., & Foreyt, J. P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.3.633 · Cited by 47
Self-citationLong-term pharmacotherapy for obesity and overweight
Padwal, R., Li, S., & Lau, D. (2002) · The Cochrane Database of Systematic Reviews (Protocol) · doi:10.1002/14651858.cd004094 · Cited by 41
Metadata
- Authors
- Haddock, C., Poston, W., Dill, P., Foreyt, J., & Ericsson, M.
- Affiliations
- Saint Luke's Hospital (US)
- University of Missouri–Kansas City (US)
- Venue
- International Journal of Obesity
- Published
- 2002-02
- Volume
- 26
- Issue
- 2
- Pages
- 262-273
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2069004141
- Cited by
- 303
- References
- 23
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 12 · 2017: 13 · 2016: 9 · 2015: 17 · 2014: 8 · 2013: 21 · 2012: 15
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity pharmacotherapy, anti-obesity drugs, weight loss, amphetamine, fenfluramine, sibutramine, benzphetamine, combination therapy, placebo effect, drug efficacy comparison, methodological factors
- MeSH terms
- Amphetamines, Benzphetamine, Cyclobutanes, Fenfluramine, Humans, Obesity, Randomized Controlled Trials as Topic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.